Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NALBUPHINE vs ONFI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mixed opioid agonist-antagonist; agonist at κ-opioid receptors and antagonist/partial agonist at μ-opioid receptors.
GABA-A receptor positive allosteric modulator; increases the frequency of chloride channel opening in response to GABA.
Moderate to severe pain,Supplement to balanced anesthesia,Preoperative and postoperative analgesia,Obstetrical analgesia during labor and delivery
Treatment of seizures associated with Lennox-Gastaut syndrome,Adjunctive therapy for other seizure types
10-20 mg IV/IM/SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum total daily dose 160 mg.
Initial: 10 mg orally twice daily; may increase by 10 mg/day after 1 week to maintenance of 20–40 mg/day in two divided doses. Maximum: 60 mg/day.
Terminal elimination half-life is 5 hours; clinically, in hepatic impairment or elderly, half-life may be prolonged up to 8-10 hours.
The terminal elimination half-life of clobazam is 36–42 hours. The active metabolite N-desmethylclobazam has a half-life of 71–82 hours. The long half-life permits once-daily dosing but also leads to slow accumulation; steady-state is achieved after 2–3 weeks.
Hepatic metabolism primarily via glucuronidation and oxidative pathways; minor involvement of CYP450 enzymes.
Hepatic via CYP3A4 and CYP2C19; primary metabolite N-desmethylclobazam is active.
Primarily hepatic metabolism; <5% excreted unchanged in urine; about 70% excreted in feces via biliary elimination.
Clobazam (ONFI) undergoes extensive hepatic metabolism. Approximately 82% of the dose is eliminated in urine (as unchanged drug and metabolites) and about 11% in feces. Unchanged clobazam accounts for <1% of urinary excretion. The major metabolite, N-desmethylclobazam, is excreted primarily renally.
Approximately 50% bound to plasma proteins, primarily albumin.
Clobazam is approximately 80–90% bound to plasma proteins, primarily albumin.
2.3 L/kg; indicates extensive tissue distribution, consistent with moderate lipophilicity.
The apparent volume of distribution is approximately 100 L (range 77–120 L), or roughly 1.4 L/kg. This large Vd indicates extensive tissue distribution and accumulation in fatty tissues.
Intravenous: 100%; Intramuscular: approximately 80%; Oral: negligible (<20%) due to extensive first-pass metabolism.
Oral bioavailability is nearly complete (>90%). Clobazam is well absorbed after oral administration with only minor first-pass metabolism.
Cr Cl 30-50 m L/min: administer 75% of normal dose every 6 hours; Cr Cl <30 m L/min: administer 50% of normal dose every 8 hours.
No specific GFR-based dose adjustments; use with caution in severe impairment (Cr Cl < 30 m L/min) due to potential for increased sedation.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% or use alternative.
Mild to moderate (Child-Pugh A/B): Initial 5 mg orally twice daily; may increase by 5 mg/day after 1 week to maximum 20 mg/day. Severe (Child-Pugh C): Not recommended.
0.1-0.2 mg/kg IV/IM/SC every 3-6 hours as needed; maximum single dose 20 mg.
Clobazam (ONFI) for seizures: Age 2 to <6 years, body weight ≥12.5 kg: Initial 5 mg orally once daily; titrate to maintenance 5 mg twice daily. Age ≥6 years: Weight ≤30 kg: Initial 5 mg once daily; titrate to 5 mg twice daily (max 20 mg/day). Weight >30 kg: same as adult dosing. Administer with food.
Initiate at 50% of adult dose (5-10 mg) and titrate cautiously due to increased sensitivity and risk of respiratory depression.
Elderly (≥65 years): Initial 5 mg orally twice daily; increase slowly to lowest effective maintenance due to increased sensitivity and risk of falls. Avoid doses above 20 mg/day unless clearly necessary.
Risk of respiratory depression, particularly in opioid-naive patients; risk of dependence and abuse; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant use for patients for whom alternative treatment options are inadequate.
Respiratory depression may occur, especially in elderly, cachectic, or debilitated patients,Avoid use in patients with head injury or increased intracranial pressure,May precipitate withdrawal in opioid-dependent patients,Hypotension, biliary tract spasm, and seizure risk
Risk of respiratory depression, especially with opioids,Sedation and somnolence,Risk of abuse and dependence,Withdrawal seizures on abrupt discontinuation,Increased risk of suicidal thoughts or behavior
Hypersensitivity to nalbuphine or any component,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting,Suspected or known gastrointestinal obstruction
Hypersensitivity to clobazam or any component of formulation,Severe hepatic impairment
No significant food-drug interactions. Avoid alcohol and grapefruit juice as they may enhance CNS depression.
Avoid grapefruit and grapefruit juice as they may increase clobazam levels. No other significant food interactions are known. CNS depressant effects may be potentiated by alcohol.
FDA Category C. First trimester: Limited human data, no evidence of major malformations in animal studies at 4-6x MRHD. Second/third trimester: Chronic use may cause neonatal opioid withdrawal syndrome (NOWS) including irritability, hypertonia, tremors, poor feeding. Use only if benefit outweighs risk.
Pregnancy Category C. First trimester: increased risk of major malformations including cleft lip/palate (OR 2.0-3.0); second/third trimester: risk of neonatal withdrawal, hypotonia, poor feeding, respiratory depression, and hypothermia; consistent exposure may cause floppy infant syndrome. Late pregnancy exposure linked to neonatal benzodiazepine withdrawal syndrome.
Excreted in human milk in low concentrations (M/P ratio ~0.6). Relative infant dose estimated 0.5-1% of maternal weight-adjusted dose. Monitor infant for sedation and poor feeding. American Academy of Pediatrics considers compatible with breastfeeding with caution.
Clobazam is excreted into breast milk; M/P ratio approximately 0.5-0.6. Accumulation possible in neonates; monitor for sedation, poor feeding, apnea. Avoid if infant has impaired hepatic function or low birth weight. American Academy of Pediatrics recommends caution; use lowest effective maternal dose.
No specific dose adjustments recommended for pregnancy. Increased clearance and volume of distribution in third trimester may potentially reduce efficacy; titrate to effect. Avoid in prolonged labor due to risk of fetal bradycardia.
Increased clearance during pregnancy (CYP3A4 induction); plasma concentrations may decrease by 30-50% in third trimester. Dose adjustments often required: monitor therapeutic response and consider dose increase by 50-100% in late pregnancy; postpartum reduce to prepregnancy dose over 1-2 weeks to avoid toxicity.
Nalbuphine is a mixed agonist-antagonist opioid with a ceiling effect for respiratory depression, making it safer than pure agonists. It can precipitate withdrawal in opioid-dependent patients. Monitor for sedation and hypotension. Reversal with naloxone may be less effective. Use with caution in hepatic impairment. Not recommended for chronic pain due to psychotomimetic effects.
ONFI (clobazam) is a benzodiazepine indicated for seizures associated with Lennox-Gastaut syndrome. Titrate slowly to minimize sedation. Monitor for withdrawal symptoms upon discontinuation; taper over several weeks. Not recommended for use in patients with severe hepatic impairment (Child-Pugh C). For patients on other CNS depressants, consider dose reduction. Clobazam's active metabolite, N-desmethylclobazam, has a long half-life (36-46 hours) and can accumulate, especially in poor CYP2C19 metabolizers. In such patients, consider lower doses and monitor for excessive sedation.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sleep aids) as they can increase dizziness and drowsiness.,Do not drive or operate heavy machinery until you know how nalbuphine affects you.,Report any signs of withdrawal (e.g., restlessness, tearing, runny nose, yawning, sweating) if you have been taking other opioids.,Seek emergency care if you experience trouble breathing, severe dizziness, or hallucinations.,Do not stop abruptly; tapering may be needed to avoid withdrawal symptoms.
Take ONFI exactly as prescribed; do not stop suddenly as withdrawal seizures may occur.,Avoid alcohol and other sedatives while taking this medication due to increased risk of drowsiness and respiratory depression.,Report any unusual mood changes, depression, or suicidal thoughts to your healthcare provider.,Do not drive or operate heavy machinery until you know how ONFI affects you, as it can cause dizziness and drowsiness.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss with your doctor before using ONFI.,Store at room temperature, away from moisture and heat.
"The combination of trifluoperazine, a phenothiazine antipsychotic, with nalbuphine, a mixed opioid agonist-antagonist, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and hypotension. Trifluoperazine may enhance the depressant effects of nalbuphine on the brainstem respiratory centers and vasomotor centers. Clinically, this interaction may result in excessive sedation, respiratory compromise, and orthostatic hypotension, particularly in elderly or debilitated patients."
"Combined use of nalbuphine, a mixed opioid agonist-antagonist, with entacapone, a catechol-O-methyltransferase (COMT) inhibitor, may increase the risk of opioid-related adverse effects, including respiratory depression and sedation, due to additive central nervous system depression. Entacapone can also inhibit the metabolism of catecholamines, potentially exacerbating opioid-induced constipation and urinary retention. Clinically, patients may experience enhanced sedation or respiratory compromise, particularly in elderly or debilitated populations."
"Concomitant use of clozapine and nalbuphine may potentiate central nervous system (CNS) depression, leading to additive sedative and respiratory depressant effects. Both drugs act on the CNS via distinct mechanisms but converge on common pathways, increasing the risk of hypotension, bradycardia, and profound sedation. Clinically, patients may experience excessive drowsiness, confusion, or respiratory compromise, particularly in those with pre-existing comorbidities or concurrent use of other CNS depressants."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NALBUPHINE vs ONFI, answered by our medical review team.
NALBUPHINE is a Opioid Agonist-Antagonist that works by Mixed opioid agonist-antagonist; agonist at κ-opioid receptors and antagonist/partial agonist at μ-opioid receptors.. ONFI is a Benzodiazepine Anticonvulsant that works by GABA-A receptor positive allosteric modulator; increases the frequency of chloride channel opening in response to GABA.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NALBUPHINE and ONFI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NALBUPHINE is: 10-20 mg IV/IM/SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum total daily dose 160 mg.. The standard adult dose of ONFI is: Initial: 10 mg orally twice daily; may increase by 10 mg/day after 1 week to maintenance of 20–40 mg/day in two divided doses. Maximum: 60 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NALBUPHINE and ONFI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NALBUPHINE is classified as Category A/B. FDA Category C. First trimester: Limited human data, no evidence of major malformations in animal studies at 4-6x MRHD. Second/third trimester: Chronic use may cause neonatal opioi. ONFI is classified as Category C. Pregnancy Category C. First trimester: increased risk of major malformations including cleft lip/palate (OR 2.0-3.0); second/third trimester: risk of neonatal withdrawal, hypotonia. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.